QuidelOrtho to Sell Testing Unit in $1.5B Deal: Report
QuidelOrtho is planning to divest a testing unit for $1.5 billion, according to the Financial Times. The move signals a major strategic shift for the diagnostics company.
QuidelOrtho is moving to shed one of its testing units in a deal valued at approximately $1.5 billion, the Financial Times reported, marking one of the most significant divestitures in the diagnostics sector in recent memory. The transaction would represent a substantial restructuring effort by the medical testing company as it looks to sharpen its focus on core operations.
The planned sale underscores a broader trend among diagnostics firms to streamline portfolios following the post-pandemic normalization of testing demand. QuidelOrtho, like many of its peers, saw extraordinary revenue surges during the COVID-19 era driven by rapid antigen test sales, only to face headwinds as that demand subsided and market conditions tightened.
Read more Dell Technologies Cuts Distribution Ties With Arrow ECS →
A $1.5 billion divestiture of this scale could provide QuidelOrtho with significant capital to pay down debt, reinvest in higher-growth segments, or return value to shareholders — strategic options that analysts and investors have been watching closely as the company navigates a more challenging post-pandemic landscape. The identity of the potential buyer and a closing timeline were not immediately disclosed in the report.
The deal, if completed, would likely draw attention from competitors and investors across the in-vitro diagnostics space, where consolidation and portfolio rationalization have accelerated. QuidelOrtho has been under pressure to demonstrate a credible path to sustainable earnings growth beyond the COVID testing boom that temporarily inflated its financials.
Continue reading at SeekingAlpha.
